We have our bags packed and ready for Houston! The annual American Society of Human Genetics (ASHG) meeting is one of our most anticipated events of the year and we can’t wait to join more than 6,500 researchers, academics, clinicians, genetic counselors, healthcare providers, and others in Houston, Texas.
This year is all about showcasing exciting advances in precision medicine. Visit DNAnexus at booth #418 for exciting meet-and-greets, product demonstrations, and customer presentations on how translational informatics is accelerating the drug discovery process. We’ll be at our booth throughout the conference but you can also email us to schedule a one-on-one meeting with a DNAnexus scientist.
12:45pm – 2:00pm
Thursday, October 17
Marriott Marquis Houston, Walker Street Hunter’s Creek Room
Come hear how City of Hope, a leading comprehensive cancer center, is operationalizing value to support the translation of clinical research discoveries to the bedside in multiple therapeutic areas. With the DNAnexus ApolloTM Platform, clinicians and researchers are able to query multi-modal datasets – with an array of clinical and genomic attributes to identify and investigate specific cohorts of patients. With TGen (the Translational Genomics Research Institute) providing basic and clinical research capability support, City of Hope will be able to scale up its sequencing programs to accelerate discovery of highly qualified drug targets, identify biomarkers of disease progression and therapy response, and stratify patient populations for future clinical trials, all of which will inform clinical care and ultimately improve patient outcomes.
RSVP now to reserve your seat and meal.
- Linda Bosserman, MD, Clinical Professor at City of Hope and Editor-in-Chief of ASCO’s Journal of Oncology Practice
- Jonathan Keats, PhD, Director of Bioinformatics at TGen and Scientific Director of Briskin Center for Multiple Myeloma Research at City of Hope
- David Fenstermacher, PhD, Vice President of Precision Medicine & Data Science, DNAnexus
Activities in DNAnexus Booth #418
Demo: Unlock the Power of the UK Biobank
Wednesday, October 16, 2-3 p.m.
Friday, October 18, 10-11 a.m.
The UK Biobank includes detailed health records, imaging and other health-related data for approximately 500,000 consented patients. With a trove of information available from UK Biobank, researchers face the challenge of extracting insights and translating them into meaningful discoveries. DNAnexus Apollo for UK Biobank, a cloud-based analysis solution, handles the breadth of phenotypic data and the depth of WES data, making data exploration simpler. Join our demo hour to learn how to leverage the powerful cohort browser to explore, analyze, and visualize UK Biobank data to generate test hypotheses for discovery at scale.
Demo: End-to-End Machine Learning Development on DNAnexus
Thursday, October 17, 10:30-11:30 a.m.
Stop by our booth to hear Jason Chin, Director of Machine Learning at DNAnexus, discuss the latest AI/DL applications available on DNAnexus.
City of Hope Meet & Greet: Delivering on The Promise of Precision Medicine
Thursday, October 17, 2-3 p.m.
Come hear how City of Hope is translating clinical research discoveries from bench to bedside with the support of TGen (the Translational Genomics Research Institute), and DNAnexus Apollo. Linda Bosserman, Assistant Clinical Professor at City of Hope, and Jonathan Keats, Director of Bioinformatics at TGen and Scientific Director of the Briskin Center for Multiple Myeloma at City of Hope, will be in the DNAnexus booth, ready to answer questions.
Wednesday, October 16
|1707||Comprehensive haplotype resolved MHC |
sequences from whole genome shotgun
sequencing from single individual.
Thursday, October 17
The portrait of fully phased assembled
diploid human genome
|1663/T||A toolkit for accelerating genomic |
analysis using NGS index formats.
Friday, October 18
A scalable framework for identifying
genetic variant set associated with
polygenic-traits in UK Biobank
Customer/Partner Talk Featuring DNAnexus
Thursday, October 17
A robust and production-level
approach to haplotype-resolved
assembly of single individuals.